ParkinsonFranceV1, Main, Merge, bibRecord, 001B17

Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?

Identifieur interne : 001B17 ( Main/Merge ); précédent : 001B16; suivant : 001B18

Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?

Auteurs : J-M Senard [France] ; A. Pathak

Source :

Revue neurologique [ 0035-3787 ] ; 2010.

RBID : pubmed:20817229

English descriptors

KwdEn :
- Antiparkinson Agents (therapeutic use), Diagnosis, Differential, Humans, Multiple System Atrophy (drug therapy), Multiple System Atrophy (etiology), Parkinson Disease (complications), Shy-Drager Syndrome (drug therapy), Shy-Drager Syndrome (etiology).
MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- complications : Parkinson Disease.
- drug therapy : Multiple System Atrophy, Shy-Drager Syndrome.
- etiology : Multiple System Atrophy, Shy-Drager Syndrome.
- Diagnosis, Differential, Humans.

Abstract

The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.

Url:

http://www.hal.inserm.fr/inserm-00550867

DOI: 10.1016/j.neurol.2010.07.007
PubMed: 20817229

Links to Exploration step

pubmed:20817229

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J-M" last="Senard">J-M Senard</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse, France. senard@cict.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pathak, A" sort="Pathak, A" uniqKey="Pathak A" first="A" last="Pathak">A. Pathak</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20817229</idno>
<idno type="pmid">20817229</idno>
<idno type="doi">10.1016/j.neurol.2010.07.007</idno>
<idno type="wicri:Area/PubMed/Corpus">000A47</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A47</idno>
<idno type="wicri:Area/PubMed/Curation">000A07</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A07</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A07</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A07</idno>
<idno type="wicri:Area/Ncbi/Merge">000C07</idno>
<idno type="wicri:Area/Ncbi/Curation">000C07</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C07</idno>
<idno type="wicri:doubleKey">0035-3787:2010:Senard J:neurogenic:orthostatic:hypotension</idno>
<idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:inserm-00550867</idno>
<idno type="url">http://www.hal.inserm.fr/inserm-00550867</idno>
<idno type="wicri:Area/Hal/Corpus">000784</idno>
<idno type="wicri:Area/Hal/Curation">000784</idno>
<idno type="wicri:Area/Hal/Checkpoint">000637</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000637</idno>
<idno type="wicri:doubleKey">0035-3787:2010:Senard J:neurogenic:orthostatic:hypotension</idno>
<idno type="wicri:Area/Main/Merge">001B17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J-M" last="Senard">J-M Senard</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse, France. senard@cict.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pathak, A" sort="Pathak, A" uniqKey="Pathak A" first="A" last="Pathak">A. Pathak</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Diagnosis, Differential</term>
<term>Humans</term>
<term>Multiple System Atrophy (drug therapy)</term>
<term>Multiple System Atrophy (etiology)</term>
<term>Parkinson Disease (complications)</term>
<term>Shy-Drager Syndrome (drug therapy)</term>
<term>Shy-Drager Syndrome (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Shy-Drager Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Shy-Drager Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Diagnosis, Differential</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.</div>
</front>
</TEI>
<double doi="10.1016/j.neurol.2010.07.007"><HAL><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING">  <orgName>Service de Pharmacologie Clinique</orgName>
  <desc>    <address>      <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-300075" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID">  <orgName>CHU Toulouse [Toulouse]</orgName>
  <desc>    <address>      <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING">  <orgName>Service de Pharmacologie Clinique</orgName>
  <desc>    <address>      <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-300075" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID">  <orgName>CHU Toulouse [Toulouse]</orgName>
  <desc>    <address>      <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:inserm-00550867</idno>
<idno type="halId">inserm-00550867</idno>
<idno type="halUri">http://www.hal.inserm.fr/inserm-00550867</idno>
<idno type="url">http://www.hal.inserm.fr/inserm-00550867</idno>
<idno type="doi">10.1016/j.neurol.2010.07.007</idno>
<date when="2010-10">2010-10</date>
<idno type="wicri:Area/Hal/Corpus">000784</idno>
<idno type="wicri:Area/Hal/Curation">000784</idno>
<idno type="wicri:Area/Hal/Checkpoint">000637</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000637</idno>
<idno type="wicri:doubleKey">0035-3787:2010:Senard J:neurogenic:orthostatic:hypotension</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, Jean Michel" sort="Senard, Jean Michel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING">  <orgName>Service de Pharmacologie Clinique</orgName>
  <desc>    <address>      <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-300075" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID">  <orgName>CHU Toulouse [Toulouse]</orgName>
  <desc>    <address>      <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Pathak, Atul" sort="Pathak, Atul" uniqKey="Pathak A" first="Atul" last="Pathak">Atul Pathak</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-136659" status="INCOMING">  <orgName>Service de Pharmacologie Clinique</orgName>
  <desc>    <address>      <addrLine>37 Allées-Jules-Guesde, 31000 Toulouse</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
  <listRelation>    <relation active="#struct-300075" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-300075" type="direct"><org type="institution" xml:id="struct-300075" status="VALID">  <orgName>CHU Toulouse [Toulouse]</orgName>
  <desc>    <address>      <addrLine>330 Avenue de Grande Bretagne, TSA 40031, 31059 Toulouse Cedex 09</addrLine>
      <country key="FR"></country>
    </address>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1016/j.neurol.2010.07.007</idno>
<series><title level="j">Revue Neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date type="datePub">2010-10</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.</div>
</front>
</TEI>
</HAL>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J-M" last="Senard">J-M Senard</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse, France. senard@cict.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pathak, A" sort="Pathak, A" uniqKey="Pathak A" first="A" last="Pathak">A. Pathak</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20817229</idno>
<idno type="pmid">20817229</idno>
<idno type="doi">10.1016/j.neurol.2010.07.007</idno>
<idno type="wicri:Area/PubMed/Corpus">000A47</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A47</idno>
<idno type="wicri:Area/PubMed/Curation">000A07</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A07</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A07</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A07</idno>
<idno type="wicri:Area/Ncbi/Merge">000C07</idno>
<idno type="wicri:Area/Ncbi/Curation">000C07</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C07</idno>
<idno type="wicri:doubleKey">0035-3787:2010:Senard J:neurogenic:orthostatic:hypotension</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J-M" last="Senard">J-M Senard</name>
<affiliation wicri:level="3"><nlm:affiliation>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse, France. senard@cict.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pathak, A" sort="Pathak, A" uniqKey="Pathak A" first="A" last="Pathak">A. Pathak</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Diagnosis, Differential</term>
<term>Humans</term>
<term>Multiple System Atrophy (drug therapy)</term>
<term>Multiple System Atrophy (etiology)</term>
<term>Parkinson Disease (complications)</term>
<term>Shy-Drager Syndrome (drug therapy)</term>
<term>Shy-Drager Syndrome (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Shy-Drager Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Multiple System Atrophy</term>
<term>Shy-Drager Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Diagnosis, Differential</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B17 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001B17 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:20817229
   |texte=   Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:20817229" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?

Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.